Johnson & Johnson Reports Q1 2024 Results

Johnson & Johnson (JNJ) PT Lowered to $175 at RBC Capital

RBC Capital analyst Shagun Singh lowered the price target on Johnson & Johnson (NYSE: JNJ) to $175.00 (from $181.00) while maintaining a Outperform rating.

The analyst comments "JNJ's stock traded modestly lower post-Q1'24, where it delivered inline sales and EPS beat. JNJ tightened FY24 operational guidance... More

Johnson & Johnson (JNJ) PT Lowered to $170 at BofA Securities

BofA Securities analyst Geoff Meacham lowered the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $180.00) while maintaining a Neutral rating.

The analyst comments "JNJ shares traded down today (-2.0%; DRG -0.3%) despite a solid 1Q and reported guidance midpoint unchanged, which we suspect was due to disappointing Carvykti sales (-1% q/q) and Vision business (-3% y/y).... More

Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance

Johnson & Johnson (NYSE: JNJ) reported mixed financial results for the first quarter of 2024, with adjusted earnings per share (EPS) slightly surpassing analyst expectations, while revenue fell marginally short of estimates. The healthcare giant posted an adjusted EPS of $2.71, which was $0.07 higher than the consensus estimate of $2.64. However, quarterly revenue was a hair's breadth away from consensus, coming in at $21.38 billion against... More

Johnson & Johnson (JNJ) Tops Q1 EPS by 7c, Revenue Slightly Misses

Johnson & Johnson (NYSE: JNJ) reported Q1 EPS of $2.71, $0.07 better than the analyst estimate of $2.64. Revenue for the quarter came in at $21.38 billion versus the consensus estimate of $21.4 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.